Podcast Episodes
Back to SearchTaking Aim at MET and KRAS in NSCLC
Tejas Patil, MD, assistant professor of medical oncology at the University of Colorado Cancer Center, talks with Robert A. Figlin, MD, about new targ…
3 years, 5 months ago
Mantle Cell Lymphoma: Optimizing Current Therapies
Jonathan Cohen, MD, MS, Associate Professor, Hematology and Medical Oncology, Emory University School of Medicine, , joins OBR Editor-in-Chief Rob…
3 years, 5 months ago
COSMIC-313 trial and the Complex Treatment Landscape for Metastatic Renal Cell Cancer: How Do You Decide?
Bob Figlin, MD, and Toni Choueiri, MD, the director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, discuss the early …
3 years, 5 months ago
Finding Joy in Work: ASCO’s Career Development Resources Help Trainees Choose Their Path
Bob Figlin, MD, and Jamie Von Roenn, MD, discuss strategies for learning about the oncology specialty earlier in the training pipeline, particula…
3 years, 5 months ago
Considering an Oncology Fellowship? Listen to This First
Gerald Hsu, MD, PhD, UCSF’s hematology/oncology fellowship program director, joins Robert Figlin, MD, to talk about what fellowship programs are look…
3 years, 6 months ago
Kidney Cancer at a Crossroads: What New Trial Results Could Mean for Patients
Michael B. Atkins, MD, and Robert Figlin, MD, discuss results from the EVEREST clinical trial as well as new data on TKIs, immunotherapy, and HIF-2 …
3 years, 7 months ago
How to Choose CLL Treatments in the Frontline Setting
Danielle Brander, MD, talks with Robert Figlin, MD, about selecting frontline treatments for CLL and how she talks with patients about their treatme…
3 years, 8 months ago
Rethinking HER2-Targeted Therapy After DESTINY-04
William Gradishar, MD, talks with Robert Figlin, MD, about breast cancer research highlights from the 2022 American Society of Clinical Oncology Ann…
3 years, 8 months ago
Most Patients with BRAF-mutant Metastatic Melanoma Benefit from First-line Immunotherapy
Michael B. Atkins, MD, talks with Robert A. Figlin, MD, about the importance of sequencing therapies for patients with BRAF-positive metastatic melan…
3 years, 9 months ago
Adjuvant and Neoadjuvant Therapy for NSCLC: Who to Treat and With What Agent
Listen in as Roy Herbst, MD, PhD, shares with Robert Figlin, MD, how he approaches treatment for patients with early-stage non-small cell lung cancer…
3 years, 10 months ago